Funding innovation for treatment for rare diseases: adopting a cost-based yardstick approach. (Q37321675)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24237605%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Funding innovation for treatment for rare diseases: adopting a cost-based yardstick approach (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24237605%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24237605%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Garret Kent Fellows

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24237605%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

16 November 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24237605%20AND%20SRC:MED&resulttype=core&format=json

Orphanet Journal of Rare Diseases

1 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24237605%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24237605%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

180

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24237605%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1186/1750-1172-8-180

1 March 2020

exact match

0 references

cites work

Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3832748

An evaluation framework for funding drugs for rare diseases

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3832748

Orphan drug development: an economically viable strategy for biopharma R&D.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3832748

Pricing and reimbursement of orphan drugs: the need for more transparency

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3832748

The cost of drug development: a systematic review

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3832748

Policy alternatives for treatments for rare diseases.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3832748

Orphan drugs and the NHS: should we value rarity?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3832748

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3832748

The price of innovation: new estimates of drug development costs

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3832748

When everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3832748

What is wrong with orphan drug policies? Suggestions for ways forward.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3832748

Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3832748

Adopting orphan drugs--two dozen years of treating rare diseases.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3832748

How did uncommon disorders become 'rare diseases'? History of a boundary object

2 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24237605

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Is it time to revisit orphan drug policies?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24237605

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

What is wrong with orphan drug policies?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24237605

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1750-1172-8-180

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24237605%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

1 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24237605%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24237605%20AND%20SRC:MED&resulttype=core&format=json